–
–
Endo International announced on Monday that it was buying Par Pharmaceutical from Bonderman’s TPG Capital for $8.1 billion.
The deal gives TPG and co-investors a profit of $6 billion — after paying off $2.3 billion of debt — giving it a return of better than seven-fold on a roughly $850 million investment just three years ago…
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
By Josh Kosman
